Browsing Tag
Canaccord Genuity
23 posts
Docebo (DCBO) launches US$70m issuer bid as preliminary Q2 revenue exceeds prior guidance
Docebo plans to cancel as much as 13.8% of its stock through a largely debt-funded issuer bid while raising its 2026 revenue outlook.
System1 (AIM: SYS1) reiterates rejection of Brave Bison’s (AIM: BBSN) £43.1m takeover proposal
The target’s recovering second-half performance and debt-free balance sheet are colliding with Brave Bison’s argument that combining the companies would create a larger marketing technology platform.
Bravura Solutions (ASX: BVS) jumps 15% as FY26 EBITDA upgrade tests AIM rerating
Bravura Solutions rallied after lifting FY26 cash EBITDA to A$77m. August results must prove whether BVS has durable recurring growth.
Invinity Energy Systems wins 32 MWh US steel mill battery deal as IES stock falls
Find out how Invinity’s 32 MWh California battery deal could reshape IES stock, US steel decarbonisation and long-duration storage demand.
Beeks Financial Cloud stock gains AI edge as BKS secures third Market Edge contract
Find out how Beeks Financial Cloud’s $10m June contract run and Market Edge Intelligence wins could reshape BKS stock and exchange tech demand.
Corcept Therapeutics (NASDAQ: CORT) climbs 7% as Lifyorli launch and analyst upgrades drive cortisol re-rating
Corcept turned a stress hormone into an ovarian cancer drug. Lifyorli is launching fast and analysts are chasing, but a premium multiple prices in a lot.
Intuitive Machines (NASDAQ: LUNR) surges 11% on Cantor upgrade and Lunar Terrain Vehicle catalyst
Intuitive Machines ran 80% on a Cantor upgrade and a pending NASA contract. But the rover award just went to rivals, and the stock trades at 39x sales.
Liontown (ASX: LTR) rallies 4.7% as lithium price recovery powers Kathleen Valley thesis
LG Energy Solution exited at the worst possible moment. Lithium prices then ripped 58%. Liontown (ASX: LTR) now has Kathleen Valley margins working.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
Syntara Limited raises A$8m as ASX:SNT advances amsulostat toward Phase 2b trial
Syntara has capital, catalysts, and dilution. The real question is whether amsulostat data can shift investor trust in ASX:SNT.